Compositions for mucosal and oral administration comprising hcg fragments

Abstract

The invention relates to the field of immunology, more specifically to the field of immune-mediated disorders such as allergies, auto-immune disease, transplantation-related disease and other inflammatory diseases. The invention in particular relates to the systemic treatment of inflammatory disease by oral or mucosal administration of a pharmaceutical composition with a gene-regulatory peptide. The invention provides a pharmaceutical composition in a form for mucosal application for the treatment of a subject suffering from disease, the pharmaceutical composition comprising a pharmacologically effective amount of a gene-regulatory peptide or a functional analogue thereof together with a pharmaceutically acceptable diluent.

1 . A pharmaceutical composition in a form for mucosal application for the treatment of a subject suffering from a disease, said pharmaceutical composition comprising:
 a pharmacologically effective amount of a gene-regulatory peptide or a functional analogue thereof together with a pharmaceutically acceptable diluent.   
     
     
         2 . The pharmaceutical composition of  claim 1 , wherein said form for mucosal application is selected from the group of sprays, liquids, and gels. 
     
     
         3 . The pharmaceutical composition of  claim 1 , wherein said pharmaceutical composition is in a form for oral administration. 
     
     
         4 . The pharmaceutical composition of  claim 3 , wherein said form for oral administration is selected from the group consisting of capsules, tablets, liquids, oral suspensions, emulsions, and powders. 
     
     
         5 . The pharmaceutical composition of  claim 1 , wherein said gene-regulatory peptide or functional analogue modulates translocation and/or activity of a gene transcription factor. 
     
     
         6 . The pharmaceutical composition of  claim 5 , wherein said gene transcription factor comprises an NFκB/Rel protein. 
     
     
         7 . The pharmaceutical composition of  claim 6 , wherein translocation and/or activity of said NFκB/Rel protein is inhibited. 
     
     
         8 . The pharmaceutical composition of  claim 1 , wherein said gene-regulatory peptide or functional analogue regulates expression of a gene encoding an inflammatory mediator 
     
     
         9 . The pharmaceutical composition of  claim 8 , wherein said inflammatory mediator comprises a cytokine selected from the group of TNF-α, TGF-β, interferon γ, IL-1β, IL-4, IL-5, IL6, IL-10, IL-12, IL-23 and IL-40. 
     
     
         10 - 20 . (canceled) 
     
     
         21 . The pharmaceutical composition of  claim 3 , wherein the gene-regulatory peptide modulates translocation and/or activity of a gene transcription factor. 
     
     
         22 . The pharmaceutical composition of  claim 21 , wherein the gene transcription factor comprises an NFκB/Rel protein. 
     
     
         23 . The pharmaceutical composition of  claim 22 , wherein translocation and/or activity of the NFκB/Rel protein is inhibited. 
     
     
         24 . The pharmaceutical composition of  claim 4 , wherein the gene-regulatory peptide modulates translocation and/or activity of a gene transcription factor. 
     
     
         25 . The pharmaceutical composition of  claim 24 , wherein the gene transcription factor comprises an NFκB/Rel protein. 
     
     
         26 . The pharmaceutical composition of  claim 25 , wherein translocation and/or activity of the NFκB/Rel protein is inhibited. 
     
     
         27 . The pharmaceutical composition of  claim 2 , wherein said gene-regulatory peptide or functional analogue regulates expression of a gene encoding an inflammatory mediator 
     
     
         28 . The pharmaceutical composition of  claim 27 , wherein the inflammatory mediator comprises a cytokine selected from the group of TNF-α, TGF-β, interferon γ, IL-1β, IL-4, IL-5, IL6, IL-10, IL-12, IL-23 and IL-40. 
     
     
         29 . The pharmaceutical composition of  claim 4 , wherein said gene-regulatory peptide or functional analogue regulates expression of a gene encoding an inflammatory mediator 
     
     
         30 . The pharmaceutical composition of  claim 29 , wherein the inflammatory mediator comprises a cytokine selected from the group of TNF-α, TGF-β, interferon γ, IL-1β, IL-4, IL-5, IL6, IL-10, IL-12, IL-23 and IL-40.